Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Sareum Holdings

    MCap

    GBP35m

    Last close

    GBP0.34

    ▲ 10.25 (44.09%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    VolitionRx

    MCap

    USD70m

    Last close

    USD0.85

    ▲ 0.25 (41.67%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Vivesto (OMX: VIVE)

Last close As at 24/04/2024

0.42

▲ −0.02 (−4.55%)

Market capitalisation

228m

Latest Insights

View More

Healthcare | Update

Vivesto — Turnaround strategy beginning to deliver

Healthcare | Flash note

Oasmia Pharmaceutical — Delivering on promises

Healthcare | edison tv

Oasmia Pharmaceutical: Edison Open House Healthcare 2022

Healthcare | edison tv

Oasmia Pharmaceutical – executive interview
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (9.8) (40.8) (83.9)
Relative (9.2) (46.3) (79.2)
52 week high/low SEK2.7/SEK0.3

Financials

Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2020A 0.5 (102.6) (140.3) (24.8) N/A N/A
2021A 26.2 (99.8) (132.7) (24.6) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Update

Healthcare

Oasmia Pharmaceutical — Clarity on pathway to US approval

edison tv

Healthcare

Oasmia Pharmaceutical – executive interview

Initiation

Healthcare

Oasmia Pharmaceutical — An appealing metamorphosis